A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
← catalyst calendarSponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
2actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study is being terminated due to a business decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-22 | actual | When the study began enrolling |
| Primary completion | 2025-06-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-13 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Limb Girdle Muscular Dystrophy
Intervention
- Genetic: SRP-6004 — also filed as rAAVrh74.MHCK7.DYSF.DV
Primary outcome
what the primary-completion date above is the date OFNumber of Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)
measured Baseline up to Month 60
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed